Exchange: NASDAQ·Updated 04:14 AM EDT
SILO logo

SILOSILO Pharma Inc

$5.00
$0.2875
(6.10%)
Pre-Market
Prev Close $4.71
Mkt Cap$5.3M
Vol1.00
News
all
press releases
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.read more...
Benzinga
More News
CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside
Psychedelic biotech stocks rallied after a new executive order fast-tracked drug approvals and funding.
Stocktwits
Silo Pharma Rallies After Securing Key Patent Allowance
Silo Pharma shares are trading higher Tuesday after the EPO signaled intent to grant a patent for its serotonin 4 receptor stress application.read more...
Benzinga
Why Did SILO Stock Soar 85% Today?
The European Patent Office granted a patent for the company’s novel 5-HT4 Post-Traumatic Stress Disorder (PTSD) prevention therapy.
Stocktwits
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.read more...
Benzinga
Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline UnitedHealth, Silo Pharma, Phillips 66 In Focus
U.S. stocks rose on Tuesday, following Monday's advances.read more...
Benzinga
Levi Strauss, Greenbrier And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures down, investors should watch Levi Strauss, Silo Pharma, Greenbrier, Mach Natural Resources, and Phoenix Education Partners.read more...
Benzinga
Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know
Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.read more...
Benzinga
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Stocktwits
After a Patent Win, Analysts Think This Penny Stock Can Gain 465% in 2025
Amid the dynamic biopharma landscape, this penny stock is turning heads with a game-changing patent win, and analysts are buzzing with bullish projections for its potential.
barchart.com
<
1
2
...
>

Advertisement|Remove ads.